Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 3INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 3Plasma cell 2Breast 2Other hematologic neoplasm 1Genitourinary 1

Conditions

Multiple Myeloma 1112Recurrence 195Neoplasms 89Lymphoma 89Neoplasms, Plasma Cell 88Lymphoma, Non-Hodgkin 86Leukemia, Myeloid, Acute 53Hematologic Neoplasms 51Leukemia, Lymphocytic, Chronic, B-Cell 44Leukemia 37Myelodysplastic Syndromes 33Lymphoma, Large B-Cell, Diffuse 31Hodgkin Disease 31Immunoglobulin Light-chain Amyloidosis 30Breast Neoplasms 30Precursor Cell Lymphoblastic Leukemia-Lymphoma 26Hematologic Diseases 25Prostatic Neoplasms 19Paraproteinemias 19Lymphoma, B-Cell 19Amyloidosis 19Lymphoma, Mantle-Cell 18Ovarian Neoplasms 17Carcinoma, Non-Small-Cell Lung 17Waldenstrom Macroglobulinemia 16Lung Neoplasms 16Lymphoma, Follicular 15Lymphoproliferative Disorders 14Leukemia, Myelogenous, Chronic, BCR-ABL Positive 14Blood Protein Disorders 14

Interventions

Zoledronic Acid 2Denosumab 1BHQ880 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Bone Diseases × Plasma cell × Clear all
NCT01345019 2022-11-08

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Patients With Multiple Myeloma

Amgen

Phase 3 Completed
1,718 enrolled 22 charts
Other hematologic neoplasmPlasma cellSarcoma

Blood Protein Disorders, Bone Diseases, Bone Marrow Diseases, Bone Neoplasms, Hematologic Diseases, Multiple Myeloma, Neoplasm Metastasis, Neoplasms, Neoplastic Processes, Paraproteinemias, Spinal Cord Compression, Hematologic Neoplasms, Fractures, Bone, Neoplasms, Plasma Cell

NCT00741377 2013-02-18

A Study to Assess BHQ880 in Combination With Zoledronic Acid in Relapsed or Refractory Myeloma Patients

Novartis

Phase 1 Completed
28 enrolled
Plasma cell

Bone Diseases, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡